ClinicalTrials.gg
WithdrawnNCT06329830LUNAARUpdated Sep 19, 2024

177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer

A Phase 1/2 interventional study of 177Lu-PSMA-617 and Niraparib abiraterone acetate in Metastatic Prostate Cancer, Castration-resistant Prostate Cancer and Metastatic Castration-resistant Prostate Cancer, sponsored by Baptist Health South Florida. Withdrawn at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Baptist Health South Florida · Phase 1/2, Interventional, and Treatment

How we know · 5 judgments

Why this study was withdrawn
Funding for the study was withdrawn.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms — 21 open to participants now, 31 under way, 2 of them phase 3. lutetium (¹⁷⁷Lu) vipivotide tetraxetan · Prostatic Neoplasms.

Enrollment
41st of 41
0 · median 49
Started
2024
with 7 others
Phase 1/2
8 of 41
2 open now
Registered
27th of 41
by date

Among the 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms, this one is the 41st largest by enrollment, is one of 8 that started in 2024, is one of 8 in phase 1/2, and was the 27th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

21 of the 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About lutetium (¹⁷⁷Lu) vipivotide tetraxetan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this research study is to test the safety and possible side effects of Lutetium-177 (177Lu)-Prostate-Specific Membrane Antigen (PSMA)-617 along with niraparib and abiraterone acetate plus prednisone when it is given to people diagnosed with metastatic castration-resistant prostate cancer (prostate cancer that has spread to other parts of the body and does not improve with hormonal therapies) at different dose levels. Once an optimal dose is selected, the researchers want to find out what how well these treatments work to improve survival and control the growth of the tumor.

03

Conditions studied

  • Metastatic Prostate Cancer
  • Castration-resistant Prostate Cancer
  • Metastatic Castration-resistant Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed must be obtained prior to participation in the study
  • Adults ≥ 18 years of age
  • (ECOG) performance score of 0 to 2
  • of greater than six months as determined by the treating physician
  • Evidence of castration resistant prostate cancer with histological or cytology confirmed adenocarcinoma. This can be based on prior of prostate or metastatic disease.

    1. Should have previous therapy with at least one androgen receptor pathway inhibitor in castration resistant or sensitive setting, and
    2. Should have prior therapy with at least one with taxane chemotherapy in castration resistant or sensitive setting
  • Evidence of disease progression on current therapy which is based on either:

    1. PSA progression: based on rising values at a minimum of 1-week intervals. The minimum starting value of PSA being 1 ng/mL
    2. Radiologic progression: growth of known metastases or evidence of new metastases.
  • Evidence of PSMA positive disease based on PSMA positron emission tomography (PET)/computed tomography (CT) scan utilizing radiotracers F-18 piflufolastat PSMA or Ga-68 PSMA-11. PSMA positive is defined as having at least one tumor lesion with radiotracer uptake greater than normal liver. Patients will be excluded if any lesions exceeding size criteria in short axis [organs ≥ 1 cm, lymph nodes ≥ 2.5 cm, bones (soft tissue component) ≥ 1 cm] have uptake less than or equal to uptake in normal liver.
  • Patients must have evidence of metastatic disease with at least one of the following:

    1. Metastatic disease in the bones visible on technetium-99m-MDP (methylene diphosphonate) bone scan ("bone scan") and/or
    2. Pathologically enlarged lymph nodes of any distribution and/or
    3. Visceral metastasis of any size or distribution.
  • Adequate organ function:

    1. Bone marrow reserve: (ANC) ≥ 1500 cells/microliter (uL), ≥ 100,000 cells/uL, ≥ 9 g/dL
    2. Hepatic function: total ≤ 2 × institutional (ULN), for patients with known Gilbert syndrome ≤ 3 × institutional ULN is permitted. (ALT) or aspartate transaminase (AST) ≤ 3 × institutional ULN or ≤ 5 × institutional ULN if liver metastases
    3. Renal function: estimated (eGFR) ≥ 45 mL/min
  • Able to swallow the study medication tablets whole.
  • While on study medication and for 4 months following the last dose of study medication, participants must agree to use condom and an adequate method for partner of . Participants must agree not to donate sperm while on study treatment and for a minimum of 4 months following the last dose of study medication.

Exclusion criteria

Exclusion Criteria:

  • Pathological finding consistent with small cell or neuroendocrine carcinoma of the prostate
  • Prior therapy with poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor
  • Prior therapy with 177Lu-PSMA 617 therapy. Exception: prior therapy with radium 223 is allowed if last dose was ≥ 6 months from study therapy. Note that other prior radiation therapy (such as external beam radiation therapy or brachytherapy) to prostate or other sites is allowed.
  • History of adrenal dysfunction
  • Active (i.e., progressing or requiring treatment change in the last 24 months) other than the disease being treated under study. The only allowed exceptions are:

    1. Non-muscle invasive bladder cancer
    2. Skin cancer (non-melanoma or melanoma) treated within the last 24 months that is considered completely cured
    3. Malignancy that is considered cured with minimal risk of recurrence
  • History or current diagnosis of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML)
  • Current evidence within 3 months of study consent of any of the following: severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (i.e., pulmonary embolism), or clinically significant ventricular arrhythmias.
  • Presence of sustained uncontrolled hypertension (systolic blood pressure >160 mm Hg or diastolic blood pressure >100 mm Hg). Participants with a history of hypertension are allowed, provided that blood pressure is controlled to within these limits by an antihypertensive treatment.
  • Known allergies, , or intolerance to the of Nira/AA tablets.
  • Current evidence of any medical condition that would make prednisone use .
  • Received an intervention (including investigational vaccines) or used an invasive investigational medical device within 30 days before the planned first dose of study medication
  • Participants who have had the following ≤ 28 days prior to enrollment

    1. A transfusion ( or red blood cells);
    2. Hematopoietic growth factors;
    3. Major surgery
  • Participants with known history of with 1 or more of the following:

    1. Not receiving highly active antiretroviral therapy or on antiretroviral therapy for less than 4 weeks
    2. Receiving antiretroviral therapy that may interfere with the study medication
    3. CD4 (type of white blood cell) count \<350 at screening.
    4. An acquired immunodeficiency syndrome-defining opportunistic infection within 6 months of the start of screening.
    5. Human immunodeficiency virus load >400 copies/mL
  • Known history of active or symptomatic viral hepatitis or chronic liver disease; encephalopathy, ascites or bleeding disorders secondary to hepatic dysfunction.
  • Moderate or severe hepatic impairment (Class B and C per classification system).
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    177Lu-PSMA-617 in Combination with Niraparib/Abiraterone Acetate plus Prednisone

    177Lu-PSMA-617 will be administered per standard of care at 7.4 gigabecquerel (GBq) (200 mCi) via intravenous (IV) infusion once every cycle (6 weeks) for 6 cycles. Niraparib/Abiraterone Acetate (Nira/AA) will be taken orally by the participant daily until disease progression or unacceptable toxicity. The starting dose level is 150 mg/1000 mg Nira/AA. Other dose levels include 200 mg/1000 mg, 100 mg/1000 mg, or 50 mg/500 mg Nira/AA once daily. Prednisone (5 mg) will be taken orally by the participant twice daily each day that Nira/AA is taken.

    Drug: 177Lu-PSMA-617 · Drug: Niraparib abiraterone acetate · Drug: Prednisone

Interventions

This study also gives NiraparibStudies of NiraparibNiraparib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Determination of the recommended phase 2 dose (RP2D)

    RP2D is determined based on the number of participants experiencing a dose-limiting toxicity (DLT) during phase 1. DLT is defined as any of the following treatment-related adverse events (AE) during Cycle 1, per Common Terminology Criteria for Adverse Events (CTCAE) V5. * Grade 4 thrombocytopenia or Grade ≥3 requiring platelet transfusion * Grade 4 anemia or Grade ≥3 requiring blood transfusion * Grade 4 neutropenia ≥7 days, or Grade 3/4 associated with infection or fever \>38.5°C * Seizure, any grade * Concurrent elevation of ALT/AST \>3×ULN \& bilirubin \>2×ULN, unless concurrent elevation is related to biliary obstruction or otherwise unrelated to study treatment * Grade 3 fatigue \>5 days * Grade 3 nausea \>3 days, despite optimal medical therapy * Grade ≥3 hypertension despite receiving \>2 weeks of optimal medical therapy * Grade ≥3 vomiting or diarrhea persisting \>3 days, despite optimal medical therapy * Other treatment-related Grade ≥3 non-hematologic toxicity except Grade 3 rash

    Time frame: 6 weeks

  2. Prostatic-specific antigen (PSA)-50 response rate

    PSA-50 response is defined as a decrease ≥ 50% from baseline to the lowest post-baseline PSA result. This measure will be expressed as a percent of participants who experience this response.

    Time frame: 2 years

Secondary outcomes

  1. Radiographic progression-free survival (rPFS)

    rPFS is defined as the duration of time in months from treatment initiation to the first date of documented radiographic progression using conventional imaging or death due to any cause, whichever occurs first. The radiographic progression will be assessed per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 for soft tissue and Prostate Cancer Working Group 3 (PCWG3) for bone lesions.

    Time frame: 2 years

  2. Overall survival (OS)

    OS is defined as the duration of time in months between the first dose of study therapy and death from any cause (participants who have not died will be censored at the most recent last-known-alive date).

    Time frame: 2 years

  3. PSA-80 response rate

    PSA-80 response is defined as a decrease ≥ 80% from baseline to the lowest post-baseline PSA result. This measure will be expressed as a percent of participants who experience this response.

    Time frame: 2 years

  4. Duration of response (DOR)

    DOR is defined as the duration of time in months from when criteria are met for complete response (CR) or partial response (PR) (whichever is recorded first) until the date that recurrent or progressive disease is objectively documented or expiration. RECIST 1.1 criteria will be used for soft tissue lesions and PCWG3 criteria will be used for bone lesions.

    Time frame: 2 years

  5. Objective response rate (ORR)

    ORR is defined as the percent of participants who meet criteria for CR or PR. RECIST 1.1 criteria will be used for soft tissue lesions and PCWG3 criteria will be used for bone lesions.

    Time frame: 2 years

07

Study locations

1 site
  • Miami Cancer Institute
    Miami, Florida 33176, United States
08

References and documents

Publications

  • Loap P, Loirat D, Berger F, Rodrigues M, Bazire L, Pierga JY, Vincent-Salomon A, Laki F, Boudali L, Raizonville L, Mosseri V, Jochem A, Eeckhoutte A, Diallo M, Stern MH, Fourquet A, Kirova Y. Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial. JAMA Oncol. 2022 Dec 1;8(12):1802-1808. doi: 10.1001/jamaoncol.2022.5074. PubMed 36301572 ↗
  • Sandhu S, Joshua AM, Emmett L, Crumbaker M, Bressel M, Huynh R, Banks PD, Wallace R, Hamid A, Inderjeeth AJ, Tran B, Azad A, Alipour R, Kong G, Kumar AAR, Saghebi J, Williams S, Akhurst TJ, Kicks RJ, Hofman MS. LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2023 41(16Suppl):5005.
  • Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN Jr, Yu EY, George DJ, Chi KN, Saad F, Stahl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, Urtishak KA, Francis P, Lopez-Gitlitz A, Fizazi K; GALAHAD investigators. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2022 Mar;23(3):362-373. doi: 10.1016/S1470-2045(21)00757-9. Epub 2022 Feb 4. PubMed 35131040 ↗
  • Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S; MAGNITUDE Principal Investigators. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023 Jun 20;41(18):3339-3351. doi: 10.1200/JCO.22.01649. Epub 2023 Mar 23. PubMed 36952634 ↗
  • Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Perez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ; VISION Investigators. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23. PubMed 34161051 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2024; primary completion for Oct 2026, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2024
First posted
Mar 26, 2024
StartEst.
Oct 2024
Primary completionEst.
Oct 2026
CompletionEst.
Oct 2028
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06329830
Lead sponsor
Baptist Health South Florida
Responsible party
Sponsor
First posted
Mar 26, 2024
Start date
Oct 2024 (estimated)
Primary completion
Oct 2026 (estimated)
Completion
Oct 2028 (estimated)
Last update
Sep 19, 2024

Study contacts

Rohan Garje, M.D.
principal investigator · Miami Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lutetium (¹⁷⁷Lu) vipivotide tetraxetan · Prednisone · Niraparib

Start the discussion